Loading…
Each decision rolls up every audited claim behind one longevity question — what each creator said, how it stacks up against the literature, and the verdict.
For healthy adults at standard weekly doses: Partially Supported. For those with kidney issues or active infection: not without a physician.
For BMI < 30 without cardiometabolic indication: not yet. The off-label use outruns the safety data.
TAME hasn't finished. Existing cohorts mix diabetic and non-diabetic. The pop-culture case is ahead of the trial case.
CV-outcome data in diabetics is compelling. Healthy-adult use is extrapolation.
ITP mouse-lifespan data is striking. Human longevity trials don't exist yet.
For most healthy adults under 70: no. ASPREE and ARRIVE flipped the consensus — bleed risk eats the benefit.